Pathogenesis and treatment of the adult respiratory distress syndrome

Archives of Internal Medicine

Volumn 156, Issue 1, 1996, Pages 29-38

  Fulkerson, William J ^a   MacIntyre, Neil ^a   Stamler, Jonathan ^a   Crapo, James D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALLOPURINOL; ALPHA TOCOPHEROL; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIOXIDANT; CATALASE; CENTOXIN; COPPER ZINC SUPEROXIDE DISMUTASE; CORTICOSTEROID; DETERGENT; ENDOTOXIN ANTIBODY; IBUPROFEN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; LUNG SURFACTANT; MECLOFENAMIC ACID; MONOCLONAL ANTIBODY; NITRIC OXIDE; PROSTACYCLIN; PROSTAGLANDIN E1; PROSTAGLANDIN SYNTHASE INHIBITOR; RECOMBINANT MANGANESE SUPEROXIDE DISMUTASE; RECOMBINANT PROTEIN; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR RECEPTOR; TYLOXAPOL; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ADULT RESPIRATORY DISTRESS SYNDROME; AEROSOL; ARTIFICIAL VENTILATION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EXTRACORPOREAL OXYGENATION; GRAM NEGATIVE INFECTION; HUMAN; HYPOXEMIA; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG EDEMA; LUNG INJURY; MULTICENTER STUDY; NONHUMAN; PATHOPHYSIOLOGY; PNEUMONIA; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEPSIS;

ADULT; HUMANS; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 0030029822     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.156.1.29     Document Type: Review

References (182)

1. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet. 1967; 2:319-323
2. Petty TL, Ashbaugh DG The adult respiratory distress syndrome: clinical features, factors influencing prognosis, and principles of management. Chest. 1971;60:233-239.
3. Moon UH. Pathological features following shock with delayed death Am J Pathol. 1936;12:788-797.
4. Burford TH, Burbank B. Traumatic wet lung: observations on certain physiologic fundamentals in thoracic trauma J Thorac Surg. 1945, 14:415-424.
5. Pepe PE, Potkin RT, Reus D, Hudson L, Carrico C. Clinical predictors of the adult respiratory distress syndrome. Am J Surg 1982;144:124-130.
6. Fowler A, Hamman R, Good J, et al. Adult respiratory distress syndrome: risk with common predispositions. Ann Intern Med. 1983;98:593-597.
7. Montgomery A, Stager M, Carrico C, Hudson L. Causes of mortality in patients with adult respiratory distress syndrome. Am Rev Respir Dis. 1985;132:485-489
8. Bell R, Coalson J, Smith J, Johanson W. Multiple organ system failure and infection in the adult respiratory distress syndrome. Am Intern Med. 1983.99:293-298.
9. Seidenfeld J, Pohl D, Bell R, Harris G, Johanson W. Incidence, site, and outcome of infections in patients with the adult respiratory distress syndrome. Am Rev Respir Dis 1986;134:12-16.
10. Maunder R, Kablis P, Anardi D, Hudson L. Determinants of survival in the adult respiratory distress syndrome (ARDS). Am Rev Respir Dis. 1989;139:A220. Abstract.
11. Artigas A, Carlet J, LeGall J, et al. Clinical presentation, prognostic factors, and outcome of ARDS in the European Collaborative Study (9185-87): a preliminary report. In: Zapol WM, Lemaire F, eds. Adult Respiratory Distress Syndrome. New York, NY: Marcel Dekker Inc: 1991:37-63.
12. Suchyta M, Clemmer T, Elliott C, Orme J, Weaver L. The adult respiratory distress syndrome: a report of survival and modifying factors Chest 1992;101.1074-1079
13. Bernard GR, Artigas A. European-American consensus conference on ARDS. J Crit Care Med. 1993;8:1-12
14. Lamy M, Fallat R, Koeniger E, et al. Pathologic features and mechanisms of hypoxemia in adult respiratory distress syndrome. Am Rev Respir Dis. 1976;114:267-284
15. Bachofen M, Weibel E. Alterations of the gas exchange apparatus in adult respiratory insufficiency associated with septicemia Am Rev Respir Dis. 1977;116:589-615.
16. Ratliff N, Wilson J, Mikat F, Hack D, Graham T The lung in hemorrhagic shock, IV: the role of the polymorphonuclear leukocyte Am J Pathol 1971;65:325-334.
17. Pratt PC. Pathology of the adult respiratory distress syndrome. In: Thurlbeck WM, Abel MR, eds The Lung: Structure, Function and Disease Baltimore, Md: Williams & Wilkins, 1978.43-57.
18. Pratt P, Vollmer R, Shelburne J, Crapo J. Pulmonary morphology in a multihospital collaborative extracorporeal membrane oxygenation project, I: light microscopy. Am J Pathol. 1979; 95:191-214.
19. Zapol WM, Trelstad RL, Coffey W, Tsai I, Salvador RA Pulmonary fibrosis in severe acute respiratory failure. Am Rev Respir Dis. 1979; 119:547-554.
20. Gattinoni L, Pesenti A. ARDS: the nonhomogenous lung; facts and hypothesis. Crit Care Dig 1987;6:1-4.
21. 2 and pneumonia-induced lung injury, II: properties of pulmonary surfactant. J Appl Physiol. 1989,67 357-365.
22. Pison U, Seeger W, Buchhorn R, et al Surfactant abnormalities in patients with respiratory failure after multiple trauma Am Rev Respir Dis. 1989;140 1033-1039.
23. Coalson JJ, Winter VT, Gerstmann DR Idell S, King RJ, deLemos RA Pathophysiologic, morphometric, and biochemical studies of the premature baboon with bronchopulmonary dysplasia. Am Rev Respir Dis. 1992;145:872-881.
24. Zapol WM, Kobayashi K, Snider MT, Greene R, Laver MB. Vascular obstruction causes pulmonary hypertension in severe acute respiratory failure. Chest. 1977;7:306-307.
25. Zapol WM, Snider MT. Pulmonary hypertension in severe acute respiratory failure N Engl J Med. 1977;296.476-480
26. Gattinoni L, Pesenti A, Bombino M. Relationships between lung computed tomographic density, gas exchange, and PEEP in acute respiratory failure. Anesthesiology. 1988;69:824-832.
27. Hutchinson A, Hinson J, Brigham K, Snapper J. Effect of endotoxin on airway hyperresponsiveness to aerosol histamine J Appl Physiol 1983;54:1463-1468.
28. Wright PE, Bernard GR. The role of airflow resistance in patients with the adult respiratory distress syndrome Am Rev Respir Dis. 1989; 139:1169-1174.
29. Brunet F, Dhainaut J, Devaux J, Huyghebaert MF, Villemant D, Monsallier JF. Right ventricular performance in patients with acute respiratory failure Intensive Care Med. 1988;14:474-477.
30. Craddock PR, Fehr J, Brigham KL, Kronenberg, Jacob HS. Complement and leukocyte mediated pulmonary dysfunction in hemodialysis. N Engl J Med. 1977;296:769-774.
31. Chenoweth DE, Cooper SW, Hugli TE, Stewart RW, Blackstone EH, Kirklin JW. Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med. 1981,304:497-503.
32. Till GO, Johnson KL, Kunkel R, Ward PA Intravascular activation of complement and acute lung injury, dependence on neutrophils and toxic oxygen radicals J Clin Invest 1982;69:1126-1135.
33. Henson P, Larsen G, Webster R, et al Pulmonary microvascular alterations and injury induced by complement fragments, synergistic effect of complement activation, neutrophil sequestration, and prostaglandin. Ann N Y Acad Sci 1982,384:287-300.
34. Tate R, Repine J. Neutrophils and the adult respiratory distress syndrome Am Rev Respir Dis. 1983,128:552-559
35. Dinarello CA, Gelfand JA, Wolff SM. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 1993;269:1829-1835.
36. Debets JMH, Kampmeijer R van der Linden MPMH, Buurman WA, van der Linden VJ. Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit Care Med 1989; 17:489-494.
37. Damas P, Reuter A, Gysen P, Demonty J, Lamy M, Franchimont P. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans Crit Care Med. 1989;17.975-978.
38. Taylor FB, Kosanke SO. Three clinical presentations of E coli sepsis as studied in the baboon model. In Schlag G, ed Pathophysiology of Shock, Sepsis and Organ Failure. New York. MY Springer-Verlag NY Inc; 1993:676-688.
39. Evans T, Carpenter A, Cohen J Purification of a distinctive form of endotoxin-induced nitric oxide synthase from rat liver. Proc Natl Acad Sci U S A 1992,89:5361-5365.
40. Martin WJ. Neutrophils kill pulmonary endothelial cells by a hydrogen peroxide-dependent pathway, an in vivo model of neutrophil-mediated lung injury Am Rev Respir Dis 1983; 130.209-213.
41. Visner GA, Dougall WC, Wilson JM, Burr IA, Nick HS. Regulation of MnSOD by lipopolysaccharide, interleukin-1 and tumor necrosis factor. J Biol Chem. 1990,265.2856-2864
42. Cybulsky MI, Chan MKW, Movat HZ Biology of disease: acute inflammation and microthrombosis induced by endotoxin, interleukin-1 and tumor necrosis factor and their implication in gram-negative infection. Lab Invest 1988,58. 365-378
43. Eichacker PQ, Farese A, Hoffman WD, et al Leukocyte CD11B/18 antigen-directed monoclonal antibody improves early survival and decreases hypoxemia in dogs challenged with tumor necrosis factor. Am Rev Respir Dis 1992; 145:1023-1029.
44. Engelberts I, Samyo SK, Leeuwenberg JFM, van der Linden CJ, Buurman WA. A role for ELAM-1 in the pathogenesis of MOF during septic shock. J Surg Res. 1992;53:136-144.
45. Jaeschke H, Farhood A, Smith CW Neutrophil-induced liver cell injury in endotoxin shock is a CD11b/CD18-dependent mechanism Am J Physiol. 1991,261:G1051-G1056.
46. Mulligan MS, Varani J, Dame MK, et al. Role of endothelial-leukocyte adhesion molecule (ELAM-1) in neutrophil-mediated lung injury in rats J Clin Invest 1991,88:1396-1406.
47. Halliwell B, Gutteridge JMC. Protection against oxidants in biological systems: the superoxide theory of oxygen toxicity In: Free Radicals in Biology and Medicine. 2nd ed Oxford, England: Clarendon Press; 1989.86-187.
48. Demling RH, Smith M, Gunther R, Flynt JT, Gee MH. Pulmonary injury and prostaglandin production during endotoxema in conscious sheep. Am J Physiol 1981,240:348-353
49. Henderson W Eicosanoids and lung inflammation. Am Rev Respir Dis. 1987,135:1176-1185.
50. 2 formation is increased in human sepsis syndrome Am Rev Respir Dis 1991;144:1095-1101.
51. Stephenson A, Lonigoo J, Hyers T, Webster RO, Fowler AA. Increased concentration of leukotrienes in bronchoalveolar lavage fluid of patients with ARDS or at risk for ARDS. Am Rev Respir Dis. 1988;138:714-719.
52. Burghuber O, Strifi R, Zirroli J, et al. Leukotriene inhibitors attenuate rat lung injury induced by hydrogen peroxide Am Rev Respir Dis. 1985;131.776-785.
53. Braquet P, Touqui L, Shen T Vargaftig B. Perspectives in platelet activating factor research. Pharmacol Rev. 1987,39:97-145.
54. Vercelloti G, Yin H, Gustafason K, Nelson RD, Jacob HS. Platelet-activating factor primes neutrophil responses to agonists: role in promoting neutrophil endothehal damage. Blood. 1988; 71.1100-1107.
55. Koltai M, Hosford D, Guinot P, Esanu A, Braquet P Platelet-activating factor (PAF). a review of its effects, antagonists, and possible future clinical applications. Drugs 1991,429-29, 174-204.
56. Fracica PJ. Oxygen toxicity. In: Fulkerson WJ, MacIntyre N, eds. Problems in Respiratory Care Philadelphia, Pa: JB Lippincott; 1990 90-99.
57. Freeman BA, Crapo JD. Biology of disease: free radicals and tissue injury. Lab Invest 1982,47: 412-426.
58. Cochrane G, Spragg R, Revak S. Studies on the pathogenesis of the adult respiratory distress syndrome evidence of oxidant activity in bronchoalveolar lavage fluid J Cin Invest. 1983, 71:754-761.
59. Matalon S, Egan E. Interstitial fluid volumes and albumin spaces in pulmonary oxygen toxicity J Appl Physiol 1984,57:1767-1772.
60. Cochran CG, Arken BS Polymorphonuclear leukocytes in immunologic reactions: the destruction of vascular basement membrane in vivo and in vito J Exp Med 1966;124 733-752.
61. Pacht E, Timerman A, Lykens M, Merola AJ Deficiency of alveolar fluid glutathione in patients with sepsis and the adult respiratory distress syndrome Chest. 1991;100:1397-1403.
62. Moncada S. The L-argmine: nitric oxide pathway Acta Physiol Scand. 1992;145:201-227
63. Bernard G, Lucht W, Niedermeyer M, Snapper JR, Ogletree ML, Brigham KL Effect of N-acetylcysteine on the pulmonary response to endotoxin in the awake sheep and upon in vitro granulocyte function J Clin Invest. 1984,73: 1772-1784.
64. Bunnell E, Pacht E. Oxidized glutathione is increased in the alveolar fluid of patients with the adult respiratory distress syndrome Am Rev Respir Dis 1993;148:1174-1178.
65. Moncada S, Higgs A. The L-arginine-nitric oxide pathway N Engl J Med. 1993;329 2002-2012
66. Petros A, Bennett D, Vallance P. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock Lancet. 1991,338:1557-1558.
67. Moncada S, Palmer R, Higgs E Nitric oxide: physiology, pathophysiology and pharmacology Pharmacol Rev. 1991;43:109-142.
68. Stamler JS, Singel DJ, Loscalzo J Biochemistry of nitric oxide and its redox-activated forms. Science. 1992;258:1898-1902
69. Lepoivre M, Raman JM, Henry Y Early loss of tyrosyl radical in ribonucleotide reductase of adenocarcinoma cells producing nitric oxide. J Biol Chem. 1992,267:2994-3000.
70. Stamler JS, Jaraki O, Osborne J, et al Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl Acad Sci U S A 1992,89:7674-7677.
71. Stamler JS, Simon D, Osborne J, et al. S-nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds. Proc Natl Acad Sci U S A 1992; 89:444-448.
72. Gaston B, Riley J, Drazen J, et al Endogenous nitrogen oxides and bronchodilator S-nitrosothiols in human airways. Proc Natl Acad Sci U S A. 1993;90:10957-10961.
73. Morris SL, Walsh R, Hansen J Identification and characterization of some bacterial membrane sulfhydryl groups which are targets of bacteriostatic and antibiotic action. J Biol Chem 1984;259 13590-13594.
74. Tsuno K Prato P, Kolobow T. Acute lung injury from mechanical ventilation at moderately high airway pressures J Appl Physiol. 1990, 73:123-133.
75. Corbridge TC, Wood LDH, Crawford GP, Chudoba MJ, Yanos J, Sznajder JI. Adverse effects of large tidal volume and low PEEP in canine acid aspiration Am Rev Respir Dis. 1990; 142 311-315.
76. Marini JJ. New options for the ventilatory management of acute lung injury New Horizons 1993,1.489-503.
77. American College of Chest Physician Consensus Group. Mechanical ventilation. Chest 1993, 104.1833-1859.
78. Fiehl F, Perret C. Permissive hypercapnia: how permissive should we be? Am J Respir Crit Care Med. 1994,150 1722-1737
79. Hickling K, Henderson S, Jackson R. Low mortality associated with permissive hypercapnia in severe adult respiratory distress. Intensive Care Med. 1990,16:372-377.
80. American Association of Respiratory Care Consensus Group. Positive end expiratory pressure Respir Care. 1988,33.419-527.
81. Gattinoni L, D'Andrea L, Pelosi P, Vitale G, Pesenti A, Fumagalli R Regional effects and mechanisms of positive end-expiratory pressure in early adult respiratory distress syndrome JAMA. 1993; 269:2122-2127.
82. Cole AGH, Weller SF, Sykes MK. Inverse ratio ventilation compared with PEEP in adult respiratory failure. Intensive Care Med. 1984,10:227-232.
83. MacIntyre NR Intrinsic positive end expiratory pressure. Prob Respir Care. 1991;4:44-51.
84. American Association of Respiratory Care Consensus Group. Essentials of a mechanical ventilator. Respir Care. 1992,37:999-1057.
85. Abraham E, Yoshihara G Cardiorespiratory effects of pressure controlled ventilation in respiratory failure. Chest. 1990;98 1445-1449
86. MacIntyre NR, Gropper G, Westfall T Combining pressure limiting and cycling features in a patient interactive mechanical breath. Crit Care Med. 1994,22 353-357
87. Marini JJ Strategies to minimize breathing effort during mechanical ventilation. Crit Care Clin. 1990;6:635-661.
88. MacIntyre NR. Respiratory function during pressure support ventilation Chest. 1986;89:677-683.
89. Coghill CH, Haywood JL, Chatburn RL, Carlo WA. Neonatal pediatric high frequency ventilation: principles and practice. Respir Care. 1991; 35:596-612
90. MacIntyre N, Follett J, Deitz J, Lawlor B. Jet ventilation at 100 breaths per minute in adult respiratory failure. Am Rev Respir Dis. 1986, 134:897-901
91. Smith RB Continuous flow apneic ventilation. Respir Care. 1987;32:458-465.
92. Burke WC, Nahum A, Ravenscroft S. Modes of tracheal gas insufflation. Am Rev Respir Dis. 1993;148:562-568
93. Hurwitz A, Bergofsky E, Vomero E. Airway insufflation: increasing flow rates progressively reduce dead space in respiratory failure. Am Rev Respir Dis. 1991,144:1229-1233.
94. Mitchell JP, Schuster D, Calandrino F, Schuster DP. Improved outcome based on fluid management in critically ill patients requiring pulmonary artery catheterization. Am Rev Respir Dis. 1992;145.990-998.
95. Schuster D, Mitchell JP, Calandrino F, Schuster DP Fluid balance during pulmonary edema: is fluid gain a marker or a cause of poor outcome? Chest. 1991;100:1068-1075.
96. Shoemaker WC, Appel P, Kram H. Prospective trial of supranormal values of survivors as therapeutic goals in high risk surgical patients. Chest. 1988;94:1176-1186
97. Tuchschmidt J, Fried J, Astiz M Rackow E. Elevation of cardiac output and oxygen delivery improves outcome in septic shock. Chest. 1992, 102:216-220
98. Ronco JJ, Phang T, Walley KR, Wiggs B, Fenwick JC, Russell JA Oxygen consumption is independent of oxygen delivery in severe adult respiratory distress syndrome. Am Rev Respir Dis. 1991;143 1267-1273
99. Appel PL, Shoemaker WC Relationship of oxygen consumption and oxygen delivery in surgical patients with ARDs Chest 1992;102:906-911.
100. Fagon J Chastre J, Hance AJ. Detection of nosocomial lung infection in ventilated patients: use of a protected specimen brush and quantitative culture techniques in 147 patients. Am Rev Respir Dis 1908;138:110-116.
101. Fagon JY, Chastre J, Hance AJ, Domart Y, Trouillet JL, Gibert C Evaluation of clinical judgement in the identification and treatment of nosocomial pneumonia in ventilated patients Chest. 1993;103.547-553
102. Zapol W, Snider M, Hill J, et al. Extracorporeal membrane oxygenation in severe acute respiratory failure: a randomized prospective study. JAMA 1979;242:2193-2196
103. Kolobow T, Solca M, Gattinoni L, Prdrnyi S. Adult respiratory distress syndrome (ARDS): why did ECMO fail? Int J Artif Organs 1981;4:58-59
104. 2 removal in severe acute respiratory failure JAMA. 1986;256 881-886.
105. 2 removal for adult respiratory distress syndrome. Am J Respir Crit Care Med. 1994;149 295-305.
106. Hirschl RB, Parent A, Tooley, et al. Liquid ventilation improves pulmonary function, gas exchange and lung injury in a model of respiratory failure. Ann Surg. 1995,22.79-88
107. Skubitz KM, Craddock PR, Hammerschmidt DE, August JT Corticosteroid black binding of chemotactic peptide to its receptor on granulocytes and cause disaggregation of granulocytes aggregates in vitro J Clin Invest 1981; 68 13-20
108. Waage A. Production and clearance of tumor necrosis factor in rats exposed to endotoxin and dexamethasone. Clin Immunol Immunopathol. 1987;45:345-355.
109. Bone RC, Fischer CJ, Clemmer TP, Slotman SJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock N Engl J Med. 1987;317:653-658
110. Bernard QR, Luce JM, Sprung CL, et al. High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med. 1987;317:1565-1570
111. Luce JM, Montgomery AB, Marks JD, Turner J, Metz CA, Murray JF. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis. 1988;133:62-68.
112. Hooper RS, Kearl RA. Established ARDS treated with a sustained course of adrenocortical steroids. Chest. 1990,97:138-143.
113. Meduri GU, Belendria JM, Estes RJ, Wunderrink RG, el Torky M, Leeper KV Jr Fibroproliferative phase of ARDS. clinical findings and effects of corticosteroids. Chest. 1991;100:943-952
114. 5 murine monoclonal IgM antibody to endotoxin in the treatment of gram negative sepsis JAMA. 1991;266:1097-1102
115. Ziegler E, Fisher C, Sprung C, et al Treatment of gram negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial. N Engl J Med 1991,324:429-436.
116. McCloskey R, Straube R, Sanders C, Smith S, Smith C Treatment of septic shock with human monoclonal antibody HA-1A Ann Intern Med. 1994,121:1-5
117. 5 in gram-negative sepsis. In: Program and Abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1991:294 Abstract 1170.
118. L, and interferon Y in the serum of patients with septic shock J Infect Dis 1990,161 982-987.
119. Casey LC, Balk R, Bone R. Plasma cytokine endotoxin levels correlate with survival in patients and with the sepsis syndrome Ann Intern Med. 1993;119:771-778.
120. Beutler B, Milsark I, Cerami. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 1985;229.869-871.
121. Tracey K, Fong Y, Hesse DG, et al. Anti-cachectin/ TNF monoclonal antibodies prevent septic shock during lethal bacteremia Nature. 1987;330: 662-664.
122. Mathison J, Woffson E, Ulevitch R. Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits J Clin Invest 1988, 8:1925-1937.
123. Olelsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson R. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990;348:550-552.
124. Alexander H, Doherty G, Buresh C, Venzon D, Norton J. A recombinant human receptor antagonist to interleukin-1 improves survival after lethal endotoxemia in mice. J Exp Med. 1991; 173.1029-1032.
125. Wakabayashi G, Gelland J, Burke J, Thompson R, Dinarello C. A specific receptor antagonist for interleukin-1 prevents E coli-induced shock FASEB J. 1991;5:338-343.
126. Fischer E, Marano M, Van Zee KJ, et al IL-1 receptor blockade improves survival and hemodynamic performance in E coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest. 1992;89:1551-1557.
127. Fisher C, Dhalnaut JF, Pribble J, Knaus W, and the IL-1 Receptor Antagonist Study Group. A study evaluating the safety and efficacy of human recombinant interieukin-1 receptor antagonist in the treatment of patients with sepsis syndrome Presented at the 13th International Symposium on Intensive Care and Emergency Medicine; March 23, 1993; Brussels, Belgium.
128. Fletcher J, Ramwell P. Modification by aspirin and indomethacin, of the hemodynamic and prostaglandin releasing effects of E coli endotoxin in the dog Br J Pharmacol 1977,61:175-181.
129. Parratt J Sturgess R E coli endotoxin shock in the cat: treatment with indomethacin. Br J Pharmacol. 1975;53 485-488
130. Fletcher J, Ramwell P Indomethacin improves survival after endotoxin in baboons. Adv Prostaglandin Thromboxane Leukot Res. 1980;7: 821-828.
131. Beck R, Abel F. Effect of ibuprofen on the course of canine endotoxin shock Circ Shock. 1987; 23:59-70.
132. Snapper JR, Hutchison AA, Ogletree ML, Brigham KL. Effects of cyclooxygenase inhibitors on the alteration of lung mechanics caused by endotoxemia in the unanesthetized sheep. J Clin Invest. 1983,72:63-76.
133. Wright P, Bernard G Mechanisms of the late hemodynamic and airway mechanics response to endotoxin in the awake sheep. Am Rev Respir Dis 1989;140 672-678
134. Bernard G, Korleg V, Chee P, Swindell B, Ford-Hutchinson AW, Tagari P Persistent generation of peptide leukotrienes in patients with the adult respiratory distress syndrome. Am Rev Respir Dis. 1991,144:263-267.
135. Coggeshall J, Christmas B, Lefferts P, et al. Effect of inhibition of 5-lipoxygenase metabolism of arachidonic acid on response to endotoxemia in sheep. J Appl Physiol 1988;65:1351-1359
136. Hoekstra R, Jackson J, Myers T, et al Improved neonatal survival following multiple doses of bovine surfactant in very premature neonates at risk for respiratory distress syndrome Pediatrics. 1991,88:10-18.
137. Liechty E, Donovan E, Purhoit D, et al. Reduction of neonatal mortality after doses of bovino surfactant in low birth weight neonates with respiratory distress syndrome. Pediatrics. 1991, 88:19-28.
138. Corbet A, Bucciarelli R, Goldman S, Mammel M, Wold D, Long W. Decreased mortality among small premature infants treated at birth with a single dose of synthetic surfactant: a multicenter controlled trial. J Pediatr. 1991,118 227-234.
139. Benson BJ, Dobbs LG, Ansfield MJ. Immunopharmacology of lung surfactant. In: Newball HH, ed Immunopharmacology of the Lung. New York, NY Marcel Dekker Inc. 1985:209-241.
140. Thomassen MJ, Meeker DP, Antal JM. Connors MJ, Wiedemann HP Synthetic surfactant (Exosurf) inhibits endotoxin-stimulated cytokine secretion by human alveolar macrophages. Am J Respir Cell Mol Biol 1992,7:257-260.
141. Van Daal GJ, So KL, Gommers D, et al. Intratracheal surfactant administration restores gas exchange in experimental adult respiratory distress syndrome associated with viral pneumonia. Anesth Analg. 1991;72:589-595.
142. Loewen GM, Holm BA, Milanowski L, Wild LM, Notter RH, Matalon S. Alveolar hyperoxic injury in rabbits receiving exogenous surfactant. J Appl Physiol. 1989;66.1087-1092.
143. Huang YCT, Fawcett TA, Moon RE, et al. Natural surfactant and hyperoxic lung injury in primates, I physiology and biochemistry J Appl Physiol 1994,76:991-1001.
144. Fracica PJ, Piantadost CA, Duhaylongsod FG, Crapo JD, Young SL. Natural surfactant and hyperoxic lung injury in primates, II: morphometric analyses. J Appl Physiol. 1994,76.1002-1010.
145. Huang YC, Sane AC, Simonson SG, et al. Artificial surfactant attenuates hyperoxic lung injury in primates J Appl Physiol. 1995,78.1816-1822.
146. Ghio AJ, Fracica PH, Young SL, Piantadosi CA. Synthetic surfactant scavenges oxidants and protects against hyperoxic lung injury. J Appl Physiol 1994;77:1217-1223.
147. Wiedemann H, Baughman R, DeBoisblanc B. Multicenter trial in human sepsis-induced ARDS of an aerosolized synthetic surfactant (Exosurf®). Am Rev Respir Dis. 1992;1992;145: A184. Abstract.
148. Coleman R, MacIntyre N, Synder G, Pattishall E, Zaccaredelli D. Aerosolized characteristics of 99mTc-penletic acid (DTPA) and synthetic surfactant (Exosurf®). Chest 1994;105:1765-1769
149. Cummings J, Holm B, Hudak M, Hudak B, Ferguson W, Egan E A controlled clinical comparison of four different surfactant preparations in surfactant-deficient preterm lambs. Am Rev Respir Dis. 1992;145:999-1004.
150. McKechnie K, Furman B, Paratt J Modifications by oxygen free radical scavengers of the metabolic and cardiovascular effects of endotoxin infusion in conscious rats Circ Shock. 1986;19:429-439
151. Powell RJ, Machiedo GW, Rush BF, Dikdan GS. Effect of oxygen free radical scavengers on survival in sepsis. Am Surg. 1991,57:86-88
152. Kunimoto F, Morita T, Ogawa R, Fujita T. Inhibition of lipid peroxidation improves survival rate of endotoxemic rats. Circ Shock. 1987;21:15-22
153. Warner B, Hasselgren PO, Fischer JE. Effect of allopurinol and superoxide dismatuse on survival rate in rats with sepsis. Curr Surg. 1986; 43:292-293.
154. Broner CW, Shenep JL, Stidham GL, Stokes DC, Hildner WK. Effect of scavengers of oxygen-derived free radicals on mortality in endotoxin challenged mice. Crit Care Med. 1988;16:848-851
155. Bernard G. N-acetylcysteine in experimental and clinical acute lung injury. Am J Med. 1991;91 (suppl 3c):54-59
156. Ellis EF, Dodson LY, Police RJ. Restoration of cerebravascular responsiveness to hyperventilation by the oxygen radical scavenger N-acetylcysteine following experimental traumatic brain injury. J Neurosurg. 199;75 774-779.
157. Crapo JD, DeLong DM, Hasler GR, Drew RT. The failure of aerosolized superoxide dismutase to modify pulmonary oxygen toxicity. Am Rev Respir Dis 1977,115:1027-1033.
158. Turrens JF, Crapo JD, Freeman BA. Protection against oxygen toxicity by intravenous injection of liposome-entrapped catalase and superoxide dismutase. J Clin Invest. 1985;73:87-95.
159. Marklund SL. Human copper-containing superoxide dismutase of high molecular weight. Proc Natl Acad Sci U S A. 1982;79:7634-7638.
160. Marklund SL. Extracellular superoxide dismutase in human tissues and human cell lines. J Clin Invest. 1984;74:1398-1403
161. Marklund SL. Extracellular superoxide dismutase and other superoxide isoenzymes m lissues from nine mammalian species. Biochem J. 1984;222:649-655.
162. Marklund S, Karlsson K. Extracellular superoxide dismutase, distribution in the body and therapeutic applications. In: Advances in Experimental Medicine & Biology. Orlando, Fla. Plenum Press; 1990 1-4
163. Sandstrom J, Arlsson, Edlund A, Marklund SL. Proteolytic modification of heparin-binding affinity of extracellular superoxide dismutase Biochem J. 1993,290:623-626.
164. Oury TD, Chang L, Marklund SL, Day BJ, Crapo JD. Immunocytochemical localization of extracellular superoxide dismutase in human lung. Lab Invest. 1994;70:889-898.
165. Oury TD, Piantadosi CA and Crapo JD Cold induced brain edema in mice. J Biol Chem. 1993; 268:15394-15398.
166. 2 toxicity. Proc Natl Acad Sci U S A 1991;89:9715-9719.
167. 1 in patients with the adult respiratory distress syndrome. Chest 1989,96 114-119
168. Pison U, Lopez F, Heidelmeyer C, et al. Inhaled nitric oxide reverses hypoxic pulmonary vasoconstriction without impairing gas exchange J Appl Physiol. 1993;74 1287-1292.
169. Weitzberg E, Rudehill A, Landberg J Nitric oxide inhalation attenuates pulmonary hypertension and improves gas exchange in endotoxin shock Eur J Pharmacol. 1993;233:85-94.
170. Zayek M, Cleveland D, Morin FC. Treatment of persistent pulmonary hypertension in the newborn lamb by inhaled nitric oxide. J Pediatr. 1993; 122:743-750
171. Roberts JD, Chen T, Kawai N Inhaled nitric oxide reverses pulmonary vasoconstriction in the hypoxic and acidotic newborn lamb. Circ Res 1993,72 246-254
172. Doyle M, Hoekstra J. Oxidation of nitrogen oxides by bound dyoxygenin hemoproteins. J Inorg Biochem. 1981;14:351-358.
173. Berger J Gibson R, Redding G, Standaert TA, Clarke WR, Truog WE Effects of inhaled nitric oxide during Group B streptococcal sepsis in piglets. Am Rev Respir Dis 1993;147 1080-1086.
174. Kinsella J, Neish S, Shaffer E, Abman SH. Low-dose inhalational nitric oxide in persistent pulmonary hypertension of the newborn. Lancet. 1992;340.819-820.
175. Roberts J, Polaner D, Lang P, et al. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn Lancet. 1992,340:818-819
176. Roberts J, Long P, Bigatello L, et al. Inhaled nitric oxide in congenital heart disease. Circulation. 1993,87:447-453.
177. Pepke-Zaba J, Higenbottam T, Dinh-Xuan A, et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension Lancet. 1991;338:1173-1174.
178. Girard C, Lehot J, Pannwriwe J, et al. Inhaled nitric oxide after mitral valve replacement in patients with chronic pulmonary artery hypertension. Anesthesiology. 1992,77:880-883.
179. Adatia I, Thompson J, Landzberg M, et al Inhaled nitric oxide in chronic obstructive lung disease. Lancet. 1993,341 307-308.
180. Fratacci M, Devouitloy C, Andrivet P, et al. Responses to infusion of acetylcholine and inhalation of nitric oxide in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am Rev Respir Dis. 1992,145: A722. Abstract
181. Rich G, Murphy G, Roos C, et al. Inhaled nitric oxide: selective pulmonary vasodilation in cardiac surgical patients. Anesthesiology 1993, 78:1028-1035
182. Rossaint R, Falke K, Lopez F, Siama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med. 1993,328.399-405.